Colon Cancer – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Colon Cancer – Pipeline Review, H1 2020’, provides an overview of the Colon Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Colon Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Colon Cancer

– The report reviews pipeline therapeutics for Colon Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Colon Cancer therapeutics and enlists all their major and minor projects

– The report assesses Colon Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Colon Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Colon Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

1ST Biotherapeutics Inc

ABL Bio Inc

ACF Pharmaceuticals LLC

Actinium Pharmaceuticals Inc

Actym Therapeutics Inc

Adgero Biopharmaceuticals Holdings Inc

Aduro BioTech Inc

Advanced Cancer Therapeutics LLC

Adze Biotechnology Inc

Aeglea BioTherapeutics Inc

Affimed GmbH

Agenus Inc

AGV Discovery SAS

AIMM Therapeutics BV

Alfasigma SpA

Alligator Bioscience AB

Alpine Immune Sciences Inc

Amarin Corp Plc

Ambrx Inc

Amrita Therapeutics

ANP Technologies Inc

Aphios Corp

Apollomics Inc

AptaBio Therapeutics Inc

Arbele Ltd

Ariz Precision Medicine Inc

Ascelia Pharma AB

AskAt Inc

aTyr Pharma Inc

Aurigene Discovery Technologies Ltd

Avican Inc

Avidin Ltd

Bayer AG

Baylx Inc

Beijing Fogangren Bio-Pharm Tech Co Ltd

BeyondSpring Inc

Binjiang Pharma, Inc.

Biogazelle NV

BioMed Valley Discoveries Inc

Biomunex Pharmaceuticals

Black Diamond Therapeutics Inc

Bliss Biopharmaceutical (Hangzhou) Co Ltd

Blueprint Medicines Corp

Boehringer Ingelheim International GmbH

Bold Therapeutics Inc

Calidi Biotherapeutics Inc

Can-Fite BioPharma Ltd

Cancer Prevention Pharmaceuticals Inc

Cancure Ltd

Canget BioTekpharma LLC

CARsgen Therapeutics Ltd

Celldex Therapeutics Inc

Cellective BioTherapy Inc

Celprogen Inc

CG Oncology Inc

ChemoCentryx Inc

Chipscreen Biosciences Ltd

Clover Biopharmaceuticals

CMG Pharmaceutical Co Ltd

Codiak BioSciences Inc

Convert Pharmaceuticals SA

CStone Pharmaceuticals Co Ltd

Cureport Inc

CV6 Therapeutics (Ni) Ltd

Cytocom Inc

Cytodyn Inc

CytomX Therapeutics Inc

CZ BioMed Corp

DEKK-TEC Inc

Diazon Pharmaceuticals Inc

DiNonA Inc

Disulfican Ltd

Diverse Biotech Inc

Domainex Ltd

Dracen Pharmaceuticals Inc

Eli Lilly and Co

Emcure Pharmaceuticals Ltd

EncuraGen Inc

Enochian Biosciences Inc

EntreChem SL

EnzymeBioSystems

Epigene Therapeutics Inc

Ervaxx Ltd

Etubics Corp

Evelo Biosciences Inc

Evestra Inc

Evotec SE

F-star Biotechnology Ltd

Felicitex Therapeutics Inc

For-Robin Inc

Fujifilm Holdings Corp

Fusion Antibodies Plc

G1 Therapeutics Inc

GeoVax Labs Inc

GlaxoSmithKline Plc

GlycaNova AS

GlycoMimetics Inc

GlycoNex Inc

GlyTR Therapeutics Inc

GO Therapeutics Inc

Guangdong Zhongsheng Pharmaceutical Co Ltd

Hamlet Pharma AB

HengRui YuanZheng Bio-Technology Co Ltd

Hibiskus Biopharma Inc

HitGen LTD

Horizon Therapeutics Plc

Huabo Biopharm Co Ltd

Hummingbird Bioscience Pte Ltd

I-Mab Biopharma Co Ltd

i2 Pharmaceuticals Inc

Ikena Oncology Inc

Ildong Pharmaceutical Co Ltd

ImCheck Therapeutics SAS

Immix BioPharma Inc

Immune Modulation Inc

Immunicum AB

ImmunityBio Inc

Immunos Therapeutics AG

Immunotope Inc

IMPACT Therapeutics Inc

Infinity Pharmaceuticals Inc

Inmune Bio Inc

Innate Pharma SA

Innopharmax Inc

Intensity Therapeutics Inc

InteRNA Technologies BV

iOmx Therapeutics AG

J-Pharma Co Ltd

JenKem Technology Co Ltd

Jiangsu Atom Bioscience and Pharmaceutical Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

JN Biosciences LLC

JW Pharmaceutical Corp

Kadmon Corp LLC

KAHR medical Ltd

Karyopharm Therapeutics Inc

Kineta Inc

Kitov Pharma Ltd

Kolon Life Science Inc

Kringle Pharma Inc

Kymab Ltd

LipoSeuticals Inc

Lixte Biotechnology Holdings Inc

MabVax Therapeutics Holdings Inc

Machavert Pharmaceuticals LLC

MacroGenics Inc

Mateon Therapeutics Inc

MaxiVAX SA

Medicenna Therapeutics Corp

Medicon Pharmaceuticals Inc

Merck & Co Inc

Merck KGaA

MicroQuin Ltd

Midissia Therapeutics Inc

Millennium Pharmaceuticals Inc

Multimmune GmbH

MultiVir Inc

Nanjing Jinsirui Biotechnology Co Ltd

NED Biosystems Inc

Northern Biologics Inc

Northwest Biotherapeutics Inc

Novartis AG

Novita Pharmaceuticals Inc

Novonco Pharmaceuticals Inc

Obio Technology (Shanghai) Corp Ltd

Oceanyx Pharmaceuticals Inc

Omeros Corp

Oncocross Co Ltd

Oncorus Inc

Oncovir Inc

Oncoxx Biotech Srl

Oneness Biotech Co Ltd

Ono Pharmaceutical Co Ltd

Orano Med LLC

Orpheus Therapeutics Inc

Pacylex Pharmaceuticals Inc

Patrys Ltd

Pfizer Inc

PharmAbcine Inc

PharmaCyte Biotech Inc

Phenex Pharmaceuticals AG

Photolitec LLC

PHusis Therapeutics Inc

Pionyr Immunotherapeutics Inc

PNB Vesper Life Science Pvt Ltd

Primetime Life Sciences LLC

Protexase Therapeutics Inc

Provecs Medical GmbH

Provectus Biopharmaceuticals Inc

PTC Therapeutics Inc

Qilu Puget Sound Biotherapeutics Corp

Qu Biologics Inc

Resarci Therapeutics LLC

Resonant Therapeutics Inc

Rexahn Pharmaceuticals Inc

Riptide Bioscience Inc

Rubius Therapeutics Inc

Sagimet Biosciences

Sareum Holdings Plc

Savoy Pharmaceuticals Inc

Schrodinger LLC

Scopus BioPharma Inc

SEEKYO Therapeutics

Senex Biotechnology

SetLance srl

Shanghai Junshi Bioscience Co Ltd

Shanghai Pharmaceutical Group Co Ltd

Shaperon Inc

Shattuck Labs Inc

Shionogi & Co Ltd

Shouyao Holding Co Ltd

Sichuan Huiyang Life Science and Technology Corp

SideROS

SignPath Pharma Inc

Silicon Therapeutics LLC

Somantix BV

Soricimed Biopharma Inc

Sorrento Therapeutics Inc

Sphaera Pharma Pte Ltd

Spring Bank Pharmaceuticals Inc

Stcube Inc

Sun BioPharma Inc

Suzhou Sinovent Pharmaceuticals Co Ltd

Suzhou Stainwei Biotech Inc

Tactical Therapeutics Inc

Taiho Pharmaceutical Co Ltd

Takis Srl

Talapo Therapeutics Inc

TargaGenix Inc

Tarus Therapeutics Inc

TenCure Ltd

TeneoBio Inc

TheraBioPhama

Theralase Technologies Inc

Theravectys SA

Tianjin Hengjia Biotechnology Development Co Ltd

Tiziana Life Sciences Plc

Toray Industries Inc

Transcenta Holding Ltd

Transgene Biotek Ltd

Transgene SA

Trillium Therapeutics Inc

TVAX Biomedical Inc

Tychon Bioscience Inc

Tyg Oncology Ltd

Tyme Technologies Inc

Vault Pharma Inc

Veana Therapeutics LLC

Vernalis R&D Ltd

Viomedix LLC

Viracta Therapeutics Inc

Virogin Biotech Ltd

Well Marker Bio Co Ltd

Wellmarker Bio Co Ltd

Westwood Bioscience Inc

WntResearch AB

Wuhan Binhui Biotechnology Co Ltd

Wuhan YZY Biopharma Co Ltd

XOMA Corp

Y-mAbs Therapeutics Inc

Yuhan Corp

Zenith Epigenetics Ltd

Zovis Pharmaceuticals

Table of Contents

Table of Contents

Introduction

Colon Cancer - Overview

Colon Cancer - Therapeutics Development

Colon Cancer - Therapeutics Assessment

Colon Cancer - Companies Involved in Therapeutics Development

Colon Cancer - Drug Profiles

Colon Cancer - Dormant Projects

Colon Cancer - Discontinued Products

Colon Cancer - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Colon Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Colon Cancer – Pipeline by 1ST Biotherapeutics Inc, H1 2020

Colon Cancer – Pipeline by ABL Bio Inc, H1 2020

Colon Cancer – Pipeline by ACF Pharmaceuticals LLC, H1 2020

Colon Cancer – Pipeline by Actinium Pharmaceuticals Inc, H1 2020

Colon Cancer – Pipeline by Actym Therapeutics Inc, H1 2020

Colon Cancer – Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2020

Colon Cancer – Pipeline by Aduro BioTech Inc, H1 2020

Colon Cancer – Pipeline by Advanced Cancer Therapeutics LLC, H1 2020

Colon Cancer – Pipeline by Adze Biotechnology Inc, H1 2020

Colon Cancer – Pipeline by Aeglea BioTherapeutics Inc, H1 2020

Colon Cancer – Pipeline by Trillium Therapeutics Inc, H1 2020

Colon Cancer – Pipeline by TVAX Biomedical Inc, H1 2020

Colon Cancer – Pipeline by Tychon Bioscience Inc, H1 2020

Colon Cancer – Pipeline by Tyg Oncology Ltd, H1 2020

Colon Cancer – Pipeline by Tyme Technologies Inc, H1 2020

Colon Cancer – Pipeline by Vault Pharma Inc, H1 2020

Colon Cancer – Pipeline by Veana Therapeutics LLC, H1 2020

Colon Cancer – Pipeline by Vernalis R&D Ltd, H1 2020

Colon Cancer – Pipeline by Viomedix LLC, H1 2020

Colon Cancer – Pipeline by Viracta Therapeutics Inc, H1 2020

Colon Cancer – Pipeline by Virogin Biotech Ltd, H1 2020

Colon Cancer – Pipeline by Well Marker Bio Co Ltd, H1 2020

Colon Cancer – Pipeline by Wellmarker Bio Co Ltd, H1 2020

Colon Cancer – Pipeline by Westwood Bioscience Inc, H1 2020

Colon Cancer – Pipeline by WntResearch AB, H1 2020

Colon Cancer – Pipeline by Wuhan Binhui Biotechnology Co Ltd, H1 2020

Colon Cancer – Pipeline by Wuhan YZY Biopharma Co Ltd, H1 2020

Colon Cancer – Pipeline by XOMA Corp, H1 2020

Colon Cancer – Pipeline by Y-mAbs Therapeutics Inc, H1 2020

Colon Cancer – Pipeline by Yuhan Corp, H1 2020

Colon Cancer – Pipeline by Zenith Epigenetics Ltd, H1 2020

Colon Cancer – Pipeline by Zovis Pharmaceuticals, H1 2020

Colon Cancer – Dormant Projects, H1 2020

Colon Cancer – Dormant Projects, H1 2020 (Contd..1), H1 2020

Colon Cancer – Dormant Projects, H1 2020 (Contd..2), H1 2020

Colon Cancer – Dormant Projects, H1 2020 (Contd..3), H1 2020

Colon Cancer – Dormant Projects, H1 2020 (Contd..4), H1 2020

Colon Cancer – Dormant Projects, H1 2020 (Contd..5), H1 2020

Colon Cancer – Dormant Projects, H1 2020 (Contd..6), H1 2020

Colon Cancer – Dormant Projects, H1 2020 (Contd..7), H1 2020

Colon Cancer – Dormant Projects, H1 2020 (Contd..8), H1 2020

Colon Cancer – Dormant Projects, H1 2020 (Contd..9), H1 2020

Colon Cancer – Dormant Projects, H1 2020 (Contd..10), H1 2020

Colon Cancer – Dormant Projects, H1 2020 (Contd..11), H1 2020

Colon Cancer – Dormant Projects, H1 2020 (Contd..12), H1 2020

Colon Cancer – Dormant Projects, H1 2020 (Contd..13), H1 2020

Colon Cancer – Dormant Projects, H1 2020 (Contd..14), H1 2020

Colon Cancer – Dormant Projects, H1 2020 (Contd..15), H1 2020

Colon Cancer – Dormant Projects, H1 2020 (Contd..16), H1 2020

Colon Cancer – Dormant Projects, H1 2020 (Contd..17), H1 2020

Colon Cancer – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Colon Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports